Several provinces halt AstraZeneca vaccine for those under 55 in wake of new NACI guidelines – CTV News

TORONTO —
Several provinces have halted administration of the AstraZeneca COVID-19 vaccine to those under the age of 55 following new recommendations from Canada’s National Advisory Committee on Immunization (NACI).

On Monday, the NACI recommended pausing administration of the AstraZeneca vaccine to those under the age of 55, pending further investigation on reported cases of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT), a rare blood clotting disorder, in Europe.

“We are taking this precautionary measure while Health Canada as the regulator completes its updated risk benefit analysis based on emerging data,” Dr. Howard Njoo, deputy chief public health officer at the Public Health Agency of Canada, saidMonday during a technical briefing on the matter.

“During this time of risk assessment, Canada has other vaccine options to address the ongoing risk of COVID-19 infection.”

Following the recommendation, several provinces announced they would follow the guidance, including Alberta, Manitoba, Ontario, Quebec, British Columbia and Newfoundland and Labrador.

Prince Edward Island indicated on Monday morning it will no longer give the AstraZeneca vaccine to anyone. It had been set aside for people between the ages of 18 and 29.

Health officials in Nova Scotia said the updated recommendation will not impact vaccine rollout as the AstraZeneca vaccine is currently only being offered to people between the ages of 60 and 64.

VIPIT is a condition that refers to blood clots — including blood clots in the brain — stemming from receipt of the AstraZeneca vaccine. Symptoms include serious headache, seizure, blurred vision and shortness of breath and tend to develop between four and 16 days after receiving the vaccine.

According to the NACI, cases have been identified primarily in women under the age of 55, though cases have been reported in men as well.

Based on available information, the NACI said the fatality rate of VIPIT is about 40 per cent, but this may decrease as doctors and those receiving the vaccine are more aware of the condition.

“The exact mechanism by which the AstraZeneca vaccine triggers that is still under investigation and no other risk factors have been consistently identified in patients who develop VIPIT,” Dr. Shelley Deeks, vice-chair of the NACI, said in the briefing.

Previously, it was believed that cases of VIPIT occur in about one per million administered dosesof the vaccine. However, a recent report from the Paul Ehrlich Institute in Germany indicated it could be one in 100,000 doses.

“NACI has determined that there is substantial uncertainty about the benefit of providing AstraZeneca COVID-19 vaccine to adults under 55 years of age, given the potential risks associated with VIPIT,” Deeks said.

The NACI also recommended the continued use of the AstraZeneca vaccine among people over the age of 55 with informed consent, due to the lower risk of developing of VIPIT in older populations and the increased risk of severe COVID-19 infections among these age groups. 

Canada and many other countries had previously halted the use of the vaccine in seniors at the beginning of March, but rescinded that guidance two weeks later.

Sweden and Finland have already suspended distribution of the vaccine to those under the age of 65, while in Spain it is only administered to those between the ages of 18 and 65. In Denmark, health officials have extended their suspension of the vaccine until at least April 18.

In a statement, AstraZeneca said it respects the NACI’s decision and that patient safety “remains the company’s highest priority.”

“Regulatory authorities in the U.K., European Union, the World Health Organization and Health Canada have concluded that the benefits of using our vaccine to protect people from this deadly virus significantly outweigh the risks across all adult age groups,” the company wrote in the statement.

“Tens of millions of people have now received our vaccine across the globe. The extensive body of data from two large clinical datasets and real-world evidence demonstrate its effectiveness, reaffirming the role the vaccine can play during this public health crisis.”

In a statement, Health Canada said there have been no reports of blood clots from the AstraZeneca vaccine in this country, but noted that cases have been reported in Europe and it is now requiring “additional terms and conditions on the authorizations of the AstraZeneca and Verity Pharmaceuticals/Serum Institute of India vaccines.”

“These will include a requirement that the manufacturers conduct a detailed assessment of the benefits and risks of the vaccine by age and sex in the Canadian context,” Health Canada said in the statement. “This information will support the ongoing evaluation of these rare blood clotting events, and allow Health Canada to determine if there are specific groups of people​ who may be at higher risk.”

Last week, Health Canada noted that the vaccine is not associated with an overall increased risk of blood clots and that the benefits of the vaccine outweigh its risks.

In Monday’s statement, Health Canada noted that this guidance still stands and it is working with international partners to evaluate the incoming data.

Canada is expecting to receive 1.5 million doses of the AstraZeneca vaccine on Tuesday from the United States, which has not yet authorized it for emergency use. The shipment will represent the first doses to come from the United States.

Another 500,000 doses that were delivered from the Serum Institute of India have already been distributed.

Last week, AstraZeneca reported its vaccine was 76 per cent effective in preventing symptoms and 100 per cent effective against serious infections that result in hospitalization.

With files from CTVNews.ca producer and writer Ryan Flanagan

Let’s block ads! (Why?)

Source link